VERAXA Biotech Unveils New Data for BiTAC-ADC Platform, Expanding Cancer Therapy Pipeline

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in novel cancer therapies, has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The announcement, made on June 25, 2026, positions the company to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego, as referenced in the company’s press release.

The BiTAC-ADC platform is part of VERAXA’s broader pipeline of next-generation cancer therapies, which also includes T-cell engagers (TCEs) and other antibody-based formats. The newly released data demonstrated that BiTAC-ADC could distinguish between breast cancer cells and healthy cells in laboratory studies, showing dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results highlight its potential to address a key challenge in oncology: minimizing damage to healthy tissue while effectively targeting tumors.

“Our proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells,” the company stated. This selectivity could reduce the side effects commonly associated with conventional ADCs, which often release toxic payloads systemically. By contrast, BiTAC-ADC aims to ensure that the cytotoxic drug is activated primarily within the tumor microenvironment, sparing healthy cells.

VERAXA’s announcement comes shortly after the company began trading on the NASDAQ Capital Market under the ticker symbol VRXA, following the completion of its business combination with Voyager Acquisition Corp. The move provides VERAXA with access to public capital markets to fund its research and development efforts.

The company is presenting both its BiTAC-ADC and BiTAC-TCE platforms at the BIO International Convention, seeking strategic collaborations to advance these technologies toward clinical development. The event, a major gathering for the biopharmaceutical industry, offers VERAXA an opportunity to showcase its innovations to potential partners.

The implications of this announcement are significant for the field of targeted cancer therapy. ADCs have been a rapidly growing class of cancer treatments, but their efficacy is often limited by off-target toxicity. VERAXA’s BiTAC platform could overcome this limitation, potentially leading to safer and more effective treatments for patients. If successful in clinical trials, the technology could be applied to a wide range of cancers, including breast cancer, which was used in the proof-of-concept studies.

However, the company cautioned that the data are preliminary and that forward-looking statements involve risks and uncertainties. “These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially,” the press release noted, referencing the company’s filings with the SEC. Investors are advised to consider these factors before making investment decisions.

For more information about VERAXA Biotech and its pipeline, visit the company’s newsroom at https://ibn.fm/VRXA. Details on the BIO International Convention can be found at https://nnw.fm/APy2D.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Unveils New Data for BiTAC-ADC Platform, Expanding Cancer Therapy Pipeline.

The post VERAXA Biotech Unveils New Data for BiTAC-ADC Platform, Expanding Cancer Therapy Pipeline appeared first on citybuzz.